The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: Comparison of the effect in healthy volunteers and in HIV-infected patients

European Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2001, Pages 115-121

  Grub, Sibylle ^a   Bryson, Helen ^b   Goggin, Tim ^a   Lüdin, Eric ^a   Jorga, Karin ^a  

^a Department of Clinical Pharmacology ^*  (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Drug drug interaction; HIV; Saquinavir

Indexed keywords

ERYTHROMYCIN; GELATIN; KETOCONAZOLE; RIFAMPICIN; SAQUINAVIR;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERYTHROMYCIN; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; RIFAMPIN; SAQUINAVIR;

EID: 0035041368     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100277     Document Type: Conference Paper

References (33)

1. 1. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690
2. 2. Peng C, Ho BK, Chang TW, Chang NT (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 63:2550-2556
3. 3. Revicki DA, Moyle G, Stellbrink HJ, Barker C (1999) Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) study group. AIDS 13:851-858
4. 3. Antiviral Ther 4:35-44
5. 5. Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC (1999) Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 13:F53-58
6. 6. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM (1998) Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 study team. AIDS 30;12:F103-F109
7. 7. Barry M, Mulcahy F, Merry C, Gibbons S, Back D (1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Drug interactions. Clin Pharmacokinet 36:289-304
8. 8. Shen DD, Kunze KL, Thummel KE (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliver Rev 27:99-127
9. 9. Flexner C (2000) Dual protease inhibitor therapy in HIV-infected patients: pharmacologie rationale and clinical benefits. Annu Rev Pharmacol Toxicol 40:649-674
10. 10. Fitzsimmons ME, Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266
11. 11. Lalezari J (1998) Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J Acquir Immune Defic Syndr Hum Retrovirol 19:195-197
12. 12. Vella S, Floridia M (1998) Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 34:189-201
13. 13. Perry CM, Noble S (1998) Saquinavir soft-gel capsule formulation. Drugs 55:461-486
14. 14. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194
15. 15. Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Safety 20:147-169
16. 16. Barry M, Gibbons S, Back D, Mulcahy F (1997) Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194-209
17. 17. Collazos J, Martínez E, Mayo J, Blanco M-S (2000) Effect of ketoconazole on plasma concentrations of saquinavir. J Antimicrob Chemother 46:151-153
18. 18. Jordan WC (1998) The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load. J Natl Med Assoc 90:622-624
19. 19. Veldkamp AI, Hoetelmans RM, Beijnen JH, Mulder JW, Meenhorst PL (1999) Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 29:1586
20. 20. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM (1998) Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464
21. 21. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
22. 22. Gieschke R, Fotteler B, Buss N, Steimer J-L (1999) Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 37:75-86
23. 23. Goodman Gilman A, Rall TW, Nies AS, Taylor P (1990) Goodman and Gilman's. The pharmacological basis of therapeutics. Pergamon, New York
24. 24. Ayman OS, El-Kadi AO, Maurice H, Ong H, Souich P du (1997) Down-regulation of the hepatic cytochrome P450 by an acute inflammatory reaction: implication of mediators in human and animal serum and in the liver. Br J Pharmacol 121:1164-1170
25. 25. Renton KW (2000) Hepatic drug metabolism and immunostimulation. Toxicology 142:173-178
26. 26. El-Kadi AO, Souich P du (1998) Depression of the hepatic cytochrome P450 by an acute inflammatory reaction: characterization of the nature of mediators in human and rabbit serum, and in the liver. Life Sci 63:1361-1370
27. 27. Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430
28. 28. Gill MJ, Beall G, Beattie D (1997) Safety of saquinavir soft gelatin capsule (SQV-SGC) in combination with other antiretroviral agents: multicenter study NV15182: 24 week analysis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 Sept-1 Oct, Toronto
29. 29. Wacher VJ, Wu C-Y, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134
30. 30. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R (1993) Involvement of human liver cytochrome P4503A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126
31. 31. Profit L, Eagling VA, Back DJ (1999) Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627
32. 32. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF (1998) Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 19:203-209
33. 33. Schuetz EG, Schinkel AH, Relling MV (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005